Celltrion, Inc.
068270
Classement en actions
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Prix de l'action
$146.63
Capitalisation boursière
$33.44B
Changement (1 jour)
-1.52%
Changement (1 an)
23.60%
Pays
KR
Échange Celltrion, Inc. (068270)
Catégorie
Healthcare
Historique du prix de l'action pour Celltrion, Inc. (068270)
Prix de clôture le plus élevé : $130.92 le 2026-10-01
Prix de clôture le plus bas : $4.23 le 2005-07-01
Prix de clôture le plus bas : $4.23 le 2005-07-01
Historique du prix de l'action de Celltrion, Inc. de 2005 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | 9.01% |
| 2025 | 4.60% |
| 2024 | -3.56% |
| 2023 | 3.81% |
| 2022 | -20.29% |
| 2021 | -45.68% |
| 2020 | 128.22% |
| 2019 | -24.07% |
| 2018 | 8.47% |
| 2017 | 118.41% |
| 2016 | 24.48% |
| 2015 | 96.93% |
| 2014 | -5.33% |
| 2013 | 46.20% |
| 2012 | -19.43% |
| 2011 | 8.13% |
| 2010 | 134.41% |
| 2009 | 101.37% |
| 2008 | 89.98% |
| 2007 | -33.41% |
| 2006 | -27.08% |
| 2005 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.79 | -3.81% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
